CRI Genetics Appears in 3.0% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.

Answer Capsule

In November 2026, CRI Genetics appeared in 17 of 561 AI answers included in the DNA Testing Kits benchmark (3.03%). It received 4 recommendations (0.71%), with 0 Top 3 placements and 0 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.

Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. The historical results show how the figures changed across available months. Different monthly samples limit those comparisons, and conflicting AI claims require verification before corrections are proposed.

Current AI visibility

Questions This Section Answers

• How do CRI Genetics mentions, recommendations and placements compare with its DNA Testing Kits peers?

CRI Genetics recorded 17 mentions (3.03%) and 4 recommendations (0.71%) across 561 answers included in the benchmark. Top 3 placements numbered 0; first-place recommendations numbered 0. Framing among its mentions was 5 positive, 11 neutral and 1 negative.

CRI Genetics appears in a small share of benchmark answers, and its mentions are mostly neutral rather than endorsing. The gap between being mentioned and being recommended is the central issue: the company is present in conversations without being put forward as a choice. That limits its practical reach with buyers who rely on these answers.

Positioning is weaker still. The company recorded no top-three or first-place placements, so even where it surfaces, it is not framed as a leading option. The agency would treat reach and endorsement as separate problems, working first on the wording and context that surround the company in answers rather than assuming more mentions alone will help.

What changed since last month

Questions This Section Answers

• How did CRI Genetics counts and coverage differ across the available monthly snapshots?

From October 2026 to November 2026, CRI Genetics' mention count rose from 13 to 17, while its recommendation count rose from 3 to 4. The recommendation rate was 0.53% and 0.71% respectively.

The monthly record shows movement in both mentions and recommendations, with the latest month the strongest for mentions across the period shown. Recommendations also edged up, though they remain a small fraction of answers. The pattern is not a steady climb; earlier months moved in both directions.

These are separate selected samples, and the answer sets differ between months. The observed changes describe what was recorded, not why it happened, and they should not be read as evidence that any prior action worked. The agency would track the next months against the same measures before drawing conclusions about direction.

Step 1. Measure

Questions This Section Answers

• What should the agency measure and verify first for CRI Genetics?

AI answers contained 0 conflicting claims about CRI Genetics: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No conflicting claims about CRI Genetics were recorded in the captured answers, so there is no immediate fact-check queue to work through. That is a clean starting position, but it also means the measurement work should focus on where the company sits relative to competitors rather than on correcting errors.

A visibility comparison would show which rivals occupy the recommendation space and how their framing differs. A standing list of claims to verify, kept current, would let the client respond quickly if disputes appear later. The agency would set both up as baseline tools, with clear owners, so priorities rest on evidence rather than impression.

Step 2. Make the website consistent

Questions This Section Answers

• Which recorded claim differences about CRI Genetics should be verified before proposed page edits?

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

No disputed topics were supplied for this part of the analysis, so there is nothing to adjudicate at present. The useful work here is preparatory: confirming how the company is described on its own pages and in third-party sources, and resolving entity, date and source questions before any correction is considered.

Where an apparent conflict does surface, different dates or a mismatched company entity can explain it without any error by the company or a publisher. The agency would verify against current primary sources first, keep ambiguous matches out of any correction queue, and only then propose page briefs built on approved facts.

Step 3. Align the external narrative

Questions This Section Answers

• Which cited third-party pages are relevant to fact review for CRI Genetics?

These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.

Several third-party pages were selected for review because they appear alongside the company in captured answers. Citation frequency varies widely across them, and none is linked to a recorded conflicting claim. Being cited does not show that a page influenced an answer, and the current contents of each page still need checking.

The agency would review the most frequently cited pages first, confirm what they currently say about the company, and prepare evidence-backed requests only where a genuine gap or inaccuracy is found. Publishers control their own content, so requests are framed as information, not instructions, and responses are logged separately from confirmed edits.

Step 4. Optimize priority company pages

Questions This Section Answers

• Which observed CRI Genetics website pages should receive review briefs?

The company's website was cited 28 times across 15 distinct page addresses; the table shows 8 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.

The company's own pages were cited across a range of addresses, with the cost-focused blog article appearing most often. Most cited pages did not accompany a recommending answer, which suggests the site is being used for background rather than as a reason to recommend. That distinction matters more than raw citation volume.

Page briefs would draw on approved facts and the questions buyers actually ask, starting with the pages already attracting citations. The agency would check existing coverage before proposing anything new, and would treat a cited page as an opportunity to strengthen clarity, not as proof that the page currently lacks anything.

Step 5. Publish around buyer questions

Questions This Section Answers

• Which observed buyer questions support content briefs for CRI Genetics?

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

The recorded questions cluster around two themes: alternatives to a well-known competitor and the cost of a DNA test. Answers to the alternative questions did include the company and, in those cases, recommended it, while cost questions mentioned the company without a recommendation. These are answer observations, not search volume or proof of missing content.

Content briefs would address the cost questions directly, using approved pricing facts and plain explanations, and would cover the alternative-seeking questions with honest comparisons. The agency would first check whether existing pages already answer these questions well before proposing new ones, and would build each brief around the buyer's actual wording.

Our 90-day action plan

Questions This Section Answers

• How should the agency sequence the proposed CRI Genetics work and judge completion?

The first month establishes the baseline: a scorecard, a scoped fact-review register and a shortlist of pages and sources, each with an owner and a clear evidence requirement. The second month turns verified findings into approved page briefs and justified publisher requests, with confirmed edits, no-change decisions and responses recorded separately.

The third month adds buyer-question content briefs and a fresh scorecard. Delivered work is reported as work completed, kept distinct from measured answer outcomes, and any comparison across months carries the same sample caveats as this report. No outcome is promised; the plan sets up the conditions for progress and measures it honestly.

Methodology

Questions This Section Answers

• How are CRI Genetics answer metrics and citation populations defined?

This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 561 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.

An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.

The wider citation analysis covers 800 captured answers and 5891 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.

Monthly sample coverage:

The answer samples differ between months. These comparisons show how the recorded results changed; they do not establish why they changed.

The visibility figures rest on answers that met the benchmark's inclusion rules, and the exact collection dates for the original answers are unverified. A company counts as recommended only when an answer endorses it with positive wording; top-three and first-place placements sit inside those recommendations rather than adding to them.

Answers can mention several companies, so counts cannot be summed into distinct answers. Sentiment describes answer wording, not customer satisfaction. Monthly samples differ, so comparisons show what was recorded, not why. Cited pages and any disputed claims still require independent verification.

Our first three priorities

First, confirm how the company is currently described on its most-cited pages and in the third-party sources that appear alongside it, resolving entity and date questions before anything else. This keeps any later correction grounded in verified facts rather than an AI claim.

Second, prepare page briefs for the cost-focused content that attracts citations but not recommendations, using approved facts and buyer wording. Third, build buyer-question briefs around the alternative and pricing themes, checking existing coverage first. Together these target the gap between being mentioned and being recommended, which is where the evidence points.